LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain’s significant health challenges — including obesity.
Within that, the five-year trial, conducted in collaboration with Health Innovation Manchester, will also explore how weight-loss drugs impact “participants’ employment status and sick days from work,” the company said in a news release.
The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses.
The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.
Persons:
Eli Lilly, Zepbound, ”, Rachel Batterham, Wes Streeting, Streeting, “ It’s, ” Streeting, Peter Verdault, “, Dr, Dolly van Tulleken, Eli Lilly’s
Organizations:
LONDON, U.K, of Health, Social, Department for Science, Innovation, Technology, Labour government’s, Investment, National Health Services, Health Innovation, International Medical, British Health, Social Care, Covid, NHS can’t, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly, Labs
Locations:
Lilly, British, Europe